Carol Farhangfar

417 total citations
21 papers, 202 citations indexed

About

Carol Farhangfar is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Carol Farhangfar has authored 21 papers receiving a total of 202 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Cancer Research and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Carol Farhangfar's work include Cancer Genomics and Diagnostics (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Global Cancer Incidence and Screening (3 papers). Carol Farhangfar is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Global Cancer Incidence and Screening (3 papers). Carol Farhangfar collaborates with scholars based in United States, South Korea and France. Carol Farhangfar's co-authors include Funda Meric‐Bernstam, John Mendelsohn, Gordon B. Mills, Edward S. Kim, J. Jack Lee, Kathryn A. Gold, Ignacio I. Wistuba, Waun Ki Hong, Jaemoon Yang and Michael G. Rosenblum and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Clinical Cancer Research.

In The Last Decade

Carol Farhangfar

19 papers receiving 198 citations

Peers

Carol Farhangfar

ONCOL

PRM

GENET

Francesca Holt United Kingdom

Kuikui Jiang China

Raafat Alameddine Lebanon

Mark D. McKee United States

Elisabetta Landucci Italy

Carmen Barile Italy

Mingwen Huang China

P. Merle United States

Hanqi Lei China

Daniel L. Spitz United States

Francesca Holt United Kingdom

Carol Farhangfar

82 ×1.0

53 ×0.7

73 ×1.1

ONCOL

50 ×0.8

PRM

10 ×0.4

GENET

Citations per year, relative to Carol Farhangfar Carol Farhangfar (= 1×) peers Francesca Holt

Countries citing papers authored by Carol Farhangfar

Since Specialization

Citations

This map shows the geographic impact of Carol Farhangfar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Farhangfar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Farhangfar more than expected).

Fields of papers citing papers by Carol Farhangfar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Farhangfar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Farhangfar. The network helps show where Carol Farhangfar may publish in the future.

Co-authorship network of co-authors of Carol Farhangfar

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Farhangfar. A scholar is included among the top collaborators of Carol Farhangfar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Farhangfar. Carol Farhangfar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eisner, Joel R., Yuelong Guo, Yoichiro Shibata, et al.. (2024). The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2–Based Immunotherapies. The Journal of Immunology. 213(1). 29–39. 2 indexed citations

Foureau, David, et al.. (2024). Phosphodiesterase Inhibition to Sensitize Non-Small-Cell Lung Cancer to Pemetrexed: A Double-Edged Strategy. Cancers. 16(13). 2475–2475. 1 indexed citations

Eisner, Joel R., Gregory M. Mayhew, James M. Davison, et al.. (2023). Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study. Clinical Cancer Research. 29(16). 3203–3213.

Eisner, Joel R., Gregory M. Mayhew, Yoichiro Shibata, et al.. (2022). Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer. Cancer Research Communications. 2(8). 894–903. 1 indexed citations

Farhangfar, Carol, Farhang Farhangfar, James T. Symanowski, et al.. (2022). Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients. JCO Clinical Cancer Informatics. 6(6). e2200011–e2200011. 10 indexed citations

Sha, Wei, et al.. (2022). Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer. Translational Lung Cancer Research. 11(12). 2464–2476. 4 indexed citations

Jagosky, Megan H., Colin J. Anderson, James T. Symanowski, et al.. (2022). Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma. Cancer Medicine. 12(6). 7029–7038. 3 indexed citations

Burgess, Earle F., Nury Steuerwald, James T. Symanowski, et al.. (2020). Pathogenic variants in PTEN to predict for increased risk of relapse and death in patients with limited stage small cell bladder cancer.. Journal of Clinical Oncology. 38(6_suppl). 526–526.

Livingston, Michael B., Megan H. Jagosky, Myra Robinson, et al.. (2020). A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients with metastatic or unresectable soft tissue sarcoma.. Journal of Clinical Oncology. 38(15_suppl). 11519–11519. 4 indexed citations

10.

Hwang, Jimmy, et al.. (2017). Advances in Immunotherapy in the Treatment of Colorectal Cancer. 13(7). 9 indexed citations

11.

Kowalkowski, Marc, et al.. (2017). Acute care reliance among patients with advanced cancer with or without nurse navigation.. Journal of Clinical Oncology. 35(15_suppl). e18303–e18303. 1 indexed citations

12.

Farhangfar, Carol, Jimmy J. Hwang, Kathryn F. Mileham, et al.. (2017). Utilization of consultative molecular tumor board in community setting.. Journal of Clinical Oncology. 35(15_suppl). 6508–6508. 5 indexed citations

13.

Ang, Celina, Anthony F. Shields, Joanne Xiu, et al.. (2017). Molecular characteristics of hepatocellular carcinomas from different age groups. Oncotarget. 8(60). 101591–101598. 5 indexed citations

14.

Raghavan, Deepa, et al.. (2016). Patient Navigation Associated with Decreased 30-Day All-Cause Readmission. Cancer Epidemiology Biomarkers & Prevention. 25(3). 558–558. 2 indexed citations

15.

Mileham, Kathryn F., Qing Zhang, Carol Farhangfar, et al.. (2015). Abstract C80: Development of EGFR C797S mutation in serial liquid biopsy assessments in the clinical practice setting. Molecular Cancer Therapeutics. 14(12_Supplement_2). C80–C80. 1 indexed citations

16.

Sharafkhaneh, Amir, Jonghoon Lee, Diane Liu, et al.. (2013). A pilot double-blind, randomized, placebo-controlled trial of curcumin/bioperine for lung cancer chemoprevention in patients with chronic obstructive pulmonary disease. 2(3). 62–69. 2 indexed citations

17.

Meric‐Bernstam, Funda, Carol Farhangfar, John Mendelsohn, & Gordon B. Mills. (2013). Building a Personalized Medicine Infrastructure at a Major Cancer Center. Journal of Clinical Oncology. 31(15). 1849–1857. 73 indexed citations

18.

Farhangfar, Carol, et al.. (2012). The Impact of Tumor Heterogeneity on Patient Treatment Decisions. Clinical Chemistry. 59(1). 38–40. 8 indexed citations

19.

Cho, Eun-Jin, Jaemoon Yang, Khalid A. Mohamedali, et al.. (2011). Sensitive Angiogenesis Imaging of Orthotopic Bladder Tumors in Mice Using a Selective Magnetic Resonance Imaging Contrast Agent Containing VEGF121/rGel. Investigative Radiology. 46(7). 441–449. 30 indexed citations

20.

Gold, Kathryn A., Edward S. Kim, J. Jack Lee, et al.. (2011). The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration. Cancer Prevention Research. 4(7). 962–972. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact